Kornimate/medical-research-clean huggingface dataset:
oral curcumin for radiation dermatitis

Conditions: Radiation-induced Dermatitis

Summary: the purpose of the study is to determine whether curcumin, an ingredient of some foods, can prevent or reduce the severity of skin reactions (dermatitis) caused by radiation therapy. dermatitis is a common side effect of radiation treatment, but few effective treatments have been developed for it. curcumin is a natural compound found in both turmeric and curry powder. it has been used for centuries as a spice (curry), a food coloring and as a food preservative. curcumin is non-toxic and has been found to enhance the functions of normal tissues..

radiation is a toxic agent and a widely accepted form of treatment for various types of cancer. approximately half of all women with breast cancer receive radiation therapy. despite advances in medical technology, radiation therapy still causes severe skin effects. radiation dermatitis occurs in approximately 90% of patients and ranges in severity from mild redness to more severe skin changes. dermatitis is a common side effect of radiation treatment, but few effective treatments have been developed for it; currently, there is no standard treatment for the prevention of radiation-induced dermatitis. curcumin is a natural compound found in both turmeric and curry powder. it has been used for centuries as a spice (curry), a food coloring and as a food preservative. curcumin is non-toxic and has been found to enhance the functions of normal tissues.

Eligibility criteria:
inclusion criteria: * a diagnosis of non-inflammatory breast adenocarcinoma (including in situ and bilateral) * scheduled to begin radiotherapy without concurrent chemotherapy; concurrent hormone or herceptin® (trastuzumab)treatment is okay * can have been treated by lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment * can have had breast reconstruction * scheduled to receive 25-35 radiation treatment sessions (1 session per day) using standard irradiation fractionation (1.8-2.0 gy per sessions) or 16-20 radiation treatment sessions (1 session per day) using canadian irradiation fractionation (2.2-3.0 gy per session)(100, 101). * able to swallow medication. * three weeks must have elapsed after chemotherapy and surgery before the patient can begin the study * able to understand english exclusion criteria: * inflammatory breast cancer * previous radiation therapy to the breast or chest * concurrent chemotherapy treatment * concurrent treatment with anti-coagulants (e.g., coumadin®, warfarin®), or anti-egfr (human epidermal growth factor receptor) drugs (e.g. iressa® (gefitinib), erbitux® (cetuximab, c225); aspirin is allowed * known radiosensitivity syndromes (e.g., ataxia-telangiectasia) * collagen vascular disease, unhealed surgical sites, or breast infections

Keywords: oral curcumin radiation dermatitis breast cancer patients
spinal stabilization exercise effects in hypermobility

Conditions: Hypermobility Syndrome

Summary: the aim of this study is to investigate the effects of an 8-week lumbar spinal stabilization exercise program on pain, trunk muscle endurance and postural stability in women with benign joint hypermobility syndrome


Eligibility criteria:
inclusion criteria: * volunteers in an age range of 18 to 30, * being women, * having benign joint hypermobility syndrome diagnosed according to the brighton criteria, * having no contraindication to join an exercise program. exclusion criteria: * having rheumatologic or neurologic diseases, * any other pathology involving the musculoskeletal system-history of fractures, joint dislocations, sprains and strains, * associated connective tissue disorders including marfan syndrome, ehlers-danlos syndrome, osteogenesis imperfecta, * severe psychological disorders, * being pregnant, * intervention including exercise or physical therapy in the last 3 months.
microvascular effects of intravenous esmolol during postoperative atrial fibrillation

Conditions: Postoperative Atrial Fibrillation

Summary: background: postoperative atrial fibrillation (poaf) is commonplace after cardiothoracic surgery. a rate control strategy by using short-acting beta blockers is recommended as a first-line therapy in patients without hemodynamic instability. microcirculatory effects of poaf and esmolol have not been yet investigated. the investigators made the hypothesis that poaf without hemodynamic instability would induce microvascular dysfunction which could be reversed by intravenous esmolol.


Eligibility criteria:
inclusion criteria: * conventional cardiac surgery * thoracic surgery exclusion criteria: * postoperative atrial fibrillation leading to hemodynamic instability
prognostic and predictive biomarkers of therapeutic response in pancreatic tumors

Conditions: Pancreatic Tumor

Summary: pancreatic cancer is among the most serious human neoplasia and the most difficult to treat. most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month. the aim of this study is the identification of diagnosis biomarkers, predictive of the therapeutic response. this project investigate the use of molecular analyses applied to pancreatic tumor cells collected by microbiopsy under ultrasound-endoscopy, and blood cells.


Eligibility criteria:
inclusion criteria: * suspicion of pancreatic adenocarcinoma * patient \> 18 years old * social security affiliation * signed informed consent exclusion criteria: * patient in emergency situation * major person being the object of a legal protective measure or unable to express its consent

Keywords: pancreatic tumor
evaluation of the brain natriuretic peptide as a predictor of morbidity and mortality in cardiac surgery

Conditions: Coronary Artery Disease; Valvular Disease

Summary: objective: the purpose of the present study is to assess if perioperative variation of brain natriuretic peptide (bnp) levels is a predictor of mortality and morbidity after cardiac surgery.material and methods: 500 consecutive patients will be enrolled prospectively in this study before cardiac surgery under cardiopulmonary bypass. bnp levels will be measured prior to surgery and at postoperative day 1. variations of bnp levels will be analyzed to determine if it is a predictor of mortality and morbidity after cardiac surgery. this dynamic evaluation will be compared to other tools of risk stratification in cardiac surgery as the euroscore. all patients will be followed 3 years after the procedure. hypothesis: perioperative bnp variations may be more sensitive than pre- or postoperative bnp levels alone. furthermore the perioperative homeostasis will be measured to assess its impact on bnp secretion during the perioperative period.


Eligibility criteria:
inclusion criteria: * patient who need cardiac surgery * age \> 18 years exclusion criteria: * patient on mechanic ventilation before surgery * aortic dissection-congenital disease

Keywords: brain natriuretic peptide euroscore cardiac surgery cardiopulmonary bypass coronary artery disease valvular disease risk stratification in cardiac surgery
sensory characteristics and psychosocial factors related with non-specific neck musculoskeletal pain chronification

Conditions: Neck Pain

Summary: chronic pain is commonly defined as any pain which lasts more than 12 weeks. chronic non-specific neck pain (cnsnp) has no specific underlying disease causing the pain. there are neurophysiological factors that may modulate pain response and perception in the central nervous system, producing sensory changes such as the presence of temporal summation (ts) and pressure, cold or heat hyperalgesia. ts describes the progressive increase in reported pain intensity as a function of repeated noxious stimulation (e.g. thermal, electrical or mechanical). ts and hyperalgesia are measured through quantitative sensory tests (qst) where pain pressure thresholds (ppt) are measured with an algometer. the current evidence show that ppts are significantly lower compared to healthy subjects and the association between ppts, pain intensity and disability are inconsistent. further, there are psychosocial factors (catastrophizing, kinesiophobia, stress...) that may influence the pain experience. this psychosocial factors associated with chronic pain are not systematically collected in the qst literature complicating the interpretation of data. the objectives of this study are 1) to determine disability, sensory (ts and ppts) and psychosocial changes (kinesiophobia, catastrophizing, sleep quality, life quality, stress and anxiety) in the natural evolution or in the result of physiotherapy treatment in cnsnp individuals, 2) to study the correlations between disability, psychosocial and sensory factors and 3) to observe if there is a homogeneity between the subjects.


Eligibility criteria:
inclusion criteria for individuals with cnsnp were: 1. age between 18 and 65 years; 2. capable to understand, write, and speak in spanish; 3. having suffered neck pain during the last 12 weeks at least; 4. pain localized in the neck region with or without pain radiation; 5. negative spurling test; 6. negative self-administered leeds assessment of neuropathic symptoms and signs (s-lanss); 7. negative upper limb tension test for the median nerve; 8. paindetect test with non-neuropathic pain result. . exclusion criteria: 1. presence of red flag as reported in the medical history (i.e. tumor, fracture, metabolic diseases, rheumatoid arthritis, osteoporosis); 2. neck pain with cervical radiculopathy; 3. fibromyalgia syndrome, 4. previous neck surgery; 5. currently undergoing any type of pain treatment or having received physical therapy in the previous 3 months.

Keywords: chronic non-specific neck pain musculoskeletal pain psychosocial factors sensory characteristics pressure pain thresholds temporal summation
clinical evaluation of genetron idh1 pcr kit in glioma patients

Conditions: Glioma, Malignant; Glioma, Mixed

Summary: the purpose of this trail is to evaluate the performance of genetron idh1 pcr kit in glioma patients using real-time pcr method.

this trial follows the principle of synchronous blinding. the enrolled cases are coded, and the enrolled samples are detected with genetron idh1 pcr kit and sanger sequencing method. the results were determined independently according to the cutoff values or interpretation requirements provided by each method. combined with the results of clinicopathological classification, the incidence of idh1 gene r132h mutation in different subtypes was counted to evaluate the clinical performance of the genetron idh1 pcr kit.

Eligibility criteria:
inclusion criteria: 1. enroll cases in strict accordance with the requirements of the study 2. the remaining samples after routine clinical testing 3. the collection and processing of samples meet the requirements of standard laboratory operations and product instructions 4. the relevant information of the sample is complete, including sample number, gender, age, and possible clinical diagnosis information 5. each sample must have he staining results (hematoxylin-eosin staining) 6. pathological examination diagnosed as glioma, other brain tumors or normal tissues 7. number of samples: 10 pieces of each sample with a thickness of 10μm, and the tumor content is not less than 50% exclusion criteria: 1. incomplete sample information 2. severely contaminated samples 3. samples that do not meet the requirements of sample collection and processing
gastric ultrasound assessment for patients taking cannabis

Conditions: Gastric Ultrasound; Point of Care Ultrasound; Cannabis Use

Summary: the aim of this study is to perform bedside gastric point of care ultrasound (pocus) exams to assess the gastric volume and content (clear liquids vs solid food) perioperatively in patients who report cannabis use.

cannabis use in the united states has continued to increase in recent years, particularly in the adult population. ease of access through legalization paired with improved public perception has contributed to the uptick in cannabis use. the subset of cannabis users suffering from pain who present for surgery pose a risk for perioperative aspiration due to the slowing of gastric motility due to cannabis use. there is currently no adapted npo guideline to account for cannabis use. gastric ultrasound (gus) can be used as a bedside tool for assessing a patient's stomach contents and risk of aspiration. gus can identify whether a patient's stomach is empty or filled with clear liquid, thick liquid, or solid food. the volume of the stomach can be accurately calculated if there is clear liquid content. a full stomach is categorized as those with solid or thick liquid content or with clear liquid measuring more than 1.5 ml/kg body weight. as gus is noninvasive and does not pose risk to patients, it is a useful tool assessing aspiration risk in the preoperative period.

Eligibility criteria:
inclusion criteria: * any patient reporting preoperative cannabis usage within 1 month of surgery date exclusion criteria: * patient refusal to participate * patient with gastric bypass or any other gastric surgery * large hiatal hernia * patients with large ascites * patients on peritoneal dialysis * emergency surgery * pre-existing diagnosis of gastroparesis * parkinson's disease * diabetes * currently taking metformin * chronic kidney disease stage 3 or higher * creatinine ≥ 1.2 * esophageal surgery * currently taking glp1 agonist medication

Keywords: cannabis gastric ultrasound
meningitis: burden, causes, screening and prevention in rural northern uganda

Conditions: Meningitis

Summary: this study will investigate the burden, causes, diagnostics, treatments and preventive measures related to meningitis in northern uganda. we hypothesize that understanding the burden of meningitis, risk factors, diagnostics, treatments and the preventive measures will provide information regarding the gaps in care that can be addressed in order to improve the continuum of meningitis care. we hypothesize that our data will support the advocacy for the implementation of routine vaccination for the prevention of bacterial meningitis and improving guidelines for cryptococcal antigen (crag) screening for prevention of cryptococcal meningitis, which will save lives in uganda. aim 1: to prospectively collect data on 1100 patients with meningitis and meningitis symptoms who were admitted to lira regional referral hospital (lrrh) to assess burden, etiologies, pathogenesis, and outcomes of meningitis using modern diagnostic testing not previously available in uganda. aim 2: to perform crag screening of 10,000 hiv-positive patients to determine the prevalence of cryptococcal antigenemia (infection) and conduct a case control study to compare risk factors and outcomes among crag-positive patients and matched crag-negative controls based on age, sex, tb status, art experience, cd4 count, and viral load.


Eligibility criteria:
inclusion criteria: * 1100 patients who present with meningitis or meningitis symptoms, regardless of age or vulnerably status are eligible for meningitis testing. * 10,000 hiv-infected patients presenting to lrrh, lrrh hiv clinic (lidc) or nearby outpatient clinics, regardless of age or vulnerability status, are eligible for crag screening. exclusion criteria: * patients who are found not to have meningitis after initial evaluation, or are found to have other alternative diagnoses that explain their symptoms, will be excluded. * hiv-negative patients without signs or symptoms of meningitis.
a study of bortezomib as consolidation therapy in patients with multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is determination of the event-free survival with and without bortezomib consolidation therapy from the day of the first chemotherapeutic, myeloma-specific therapy measure, up to the occurrence of progression/recurrence or up to the occurrence of death.

this is a two-arm (group), open-label (all people know the identity of the intervention), prospective (a study in which the patients are identified and then followed forward in time for the outcome of the study) randomized (the study medication is assigned by chance), multi-center study. approximately 385 patients will be enrolled in this study. patients will be randomly assigned to treatment or observation group in a ratio of 1:1. the study duration from screening up to the study end is up to 27 weeks. then the patients will be observed until the last included patient has completed a 30 month post observational phase. the patients in the treatment arm will receive 4 cycles of a therapy. each cycle lasts for a 35 days. safety evaluations will include assessment of adverse events, vital signs, physical examination, electrocardiograms, and clinical laboratory tests.

Eligibility criteria:
inclusion criteria: * patients with multiple myeloma with prior therapy consisting of remission induction therapy and high dose chemotherapy followed by stem cell transplantation * women must be postmenopausal or using safe contraception methods * creatinin clearance has to be higher than 30 ml/min and whole blood count has to be within acceptable ranges exclusion criteria: * no asecretory multiple myeloma * history of allergic reactions to bortezomib or mannitol * expected life expectancy of less than 3 months * no other malignant disease beside basalioma either existing or history of * no history of severe cardio-pulmonary disease * seizures

Keywords: multiple myeloma bortezomib ps341 proteasome inhibitor consolidation therapy
impact of the use of allogeneic hematopoietic stem cell transplantation in reunion island patients: quality of life, determinants of choices and financial repercussions

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation

Summary: this project aims to document and analyse - with a three-fold anthropological, psychosocial and economical approach - the consequences of the geographical distance from mainland france on the allosct on both patients, their caregivers and the healthcare system. it is organised in 3 working packages (wp).


Eligibility criteria:
inclusion criteria: * patients diagnosed with hematological malignancy (myeloid acute leukemia, lymphoid acute leukemia, non-hodgkin lymphoma, hodgkin disease, or myelodysplasic syndrome * candidate to an allogeneic hematopoietic stem cell transplantation in mainland france ; * residing in reunion island * age \>18 year old; * who accept or not allogeneic hematopoietic * able to complete a questionnaire exclusion criteria: * opposition to participation and collection of their data * person deprived of liberty by judicial or administrative decision, and person subject to legal protection (guardianship or curators)
perceptual consequences of cochlear implant electrode-neuron interfaces

Conditions: Deafness

Summary: despite the success of cochlear implants, devices surgically placed in the inner ears of patients with severe hearing loss, there remains substantial variability in the overall speech perception outcomes for the children and adults who receive them. the main goals of this project are: i) to improve our understanding of how cochlear implants affect the developing auditory system, ii) apply that knowledge to test new methods for programming children and adults, and iii) to study how long it takes listeners to adapt to new cochlear implant programs over the short- and long-term. the results will improve our understanding of how the deafened auditory system develops with cochlear implant stimulation and advance clinical practice to improve hearing outcomes in cochlear implant listeners.


Eligibility criteria:
inclusion criteria: research subjects with a cochlear implant adults inclusion criteria * adult at least 18 years old * native speakers of american english * wears a cochlear implant manufactured by advanced bionics (clarion hi-focus i or newer), cochlear, or med-el children inclusion criteria * children at least 6 months old * native speakers of american english * wears a cochlear implant manufactured by advanced bionics (clarion hi-focus i or newer), cochlear, or med-el * for both children and adults with a cochlear implant, some study criteria might pertain to a subset of subjects, such as a specific age at which the subjects developed a hearing loss, or was implanted. exclusion criteria: exclusion for all cochlear implant subjects: * inability to provide informed consent * does not meet the inclusion criteria for a specific study protocol, such as age of onset of hearing loss, age of cochlear implantation, duration of deafness, number of active electrodes in the cochlear implant device * unable to carry out the study protocol or tasks required in the study exclusion for all normal hearing subjects: * inability to provide informed consent * hearing loss, or significant history of hearing related issues * unable to carry out the study protocol or tasks required in the study
antiproliferative effect of octreotide in patients with metastasized neuroendocrine tumors of the midgut

Conditions: Neuroendocrine Tumors

Summary: placebo-controlled prospective randomized phase iii study to investigate the antiproliferative effect of octreotide in patients with metastasized neuroendocrine tumors of the midgut


Eligibility criteria:
inclusion criteria: * therapy-naive patients with histologically confirmed diagnosis of a locally inoperable or metastasized well-differentiated neuroendocrine tumor of the midgut * curative surgery impossible * two-dimensional tumor formation assessable by computed tomography (ct) or magnetic resonance imaging (mri) * age ≥ 18 * karnofsky-index \> 60 * written informed consent * proliferation index for ki67 exclusion criteria: * hypersensitivity to octreotide * poorly differentiated or small cell neuroendocrine tumors * primary tumor outside of the midgut * prior treatment with somatostatin-analogue \> 4 weeks * prior treatment with alpha-interferon, chemotherapy, or chemoembolisation * participation in any other clinical trial * pregnancy or lactation * no secondary malignancy in anamnesis; with the exception of patients without any manifestation of the secondary malignancy (without relapse) after curative therapy within the last five years * severe decompensated organ malfunction (heart-, liver- insufficiency) other protocol-defined exclusion criteria may apply.

Keywords: double blind phase iii disease clinical trial octreotide neuroendocrine tumor cancer tumor midgut